GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » E10

Genmab AS (OCSE:GMAB) E10 : kr53.33 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genmab AS E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Genmab AS's adjusted earnings per share data for the three months ended in Dec. 2024 was kr59.640. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr53.33 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Genmab AS's average E10 Growth Rate was 29.90% per year. During the past 3 years, the average E10 Growth Rate was 31.50% per year. During the past 5 years, the average E10 Growth Rate was 41.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Genmab AS was 113.00% per year. The lowest was 31.50% per year. And the median was 47.00% per year.

As of today (2025-03-13), Genmab AS's current stock price is kr1372.50. Genmab AS's E10 for the quarter that ended in Dec. 2024 was kr53.33. Genmab AS's Shiller PE Ratio of today is 25.74.

During the past 13 years, the highest Shiller PE Ratio of Genmab AS was 477.78. The lowest was 25.74. And the median was 101.11.


Genmab AS E10 Historical Data

The historical data trend for Genmab AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS E10 Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.79 23.47 34.47 41.04 53.33

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.04 43.44 45.70 47.51 53.33

Competitive Comparison of Genmab AS's E10

For the Biotechnology subindustry, Genmab AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Shiller PE Ratio falls into.



Genmab AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=59.64/118.9000*118.9000
=59.640

Current CPI (Dec. 2024) = 118.9000.

Genmab AS Quarterly Data

per share eps CPI Adj_EPS
201503 3.640 100.200 4.319
201506 0.270 100.300 0.320
201509 2.300 100.200 2.729
201512 6.450 99.800 7.684
201603 -0.190 100.200 -0.225
201606 2.720 100.600 3.215
201609 3.060 100.200 3.631
201612 13.620 100.300 16.146
201703 0.260 101.200 0.305
201706 4.950 101.200 5.816
201709 -0.090 101.800 -0.105
201712 12.650 101.300 14.848
201803 3.200 101.700 3.741
201806 4.210 102.300 4.893
201809 2.890 102.400 3.356
201812 13.440 102.100 15.651
201903 1.170 102.900 1.352
201906 1.350 102.900 1.560
201909 8.280 102.900 9.567
201912 23.000 102.900 26.576
202003 4.090 103.300 4.708
202006 51.350 103.200 59.162
202009 8.040 103.500 9.236
202012 8.750 103.400 10.062
202103 16.610 104.300 18.935
202106 4.640 105.000 5.254
202109 13.470 105.800 15.138
202112 10.050 106.600 11.210
202203 7.050 109.900 7.627
202206 28.660 113.600 29.997
202209 39.170 116.400 40.011
202212 7.760 115.900 7.961
202303 3.190 117.300 3.234
202306 20.280 116.400 20.716
202309 31.940 117.400 32.348
202312 10.620 116.700 10.820
202403 20.180 118.400 20.265
202406 21.700 118.500 21.773
202409 19.810 118.900 19.810
202412 59.640 118.900 59.640

Add all the adjusted EPS together and divide 10 will get our e10.


Genmab AS  (OCSE:GMAB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genmab AS's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1372.50/53.33
=25.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Genmab AS was 477.78. The lowest was 25.74. And the median was 101.11.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Genmab AS E10 Related Terms

Thank you for viewing the detailed overview of Genmab AS's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.